Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | FCER2 | P06734 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 6/20 | 0.40 |
| ▸ | ACE | P12821 | 4/20 | 0.40 |
| ▸ | CPA1 | P15085 | 2/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.40 |
| ▸ | GHSR | Q92847 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318999 | 1.00 | F2 (0.46) | F2MMP9MMP8FCER2CA2 | |
| SCHEMBL7066041 | 0.86 | GHSR (0.46) | F2MMP9MMP8GHSROPRM1 | |
| SCHEMBL8906486 | 0.86 | MMP9 (0.47) | F2MMP9MMP8FCER2MME | |
| SCHEMBL8904948 | 0.83 | F2 (0.48) | F2MMP9MMP8FCER2CA2 | |
| SCHEMBL8904954 | 0.83 | F2 (0.48) | F2MMP9MMP8FCER2CA2 | |
| SCHEMBL8717333 | 0.82 | MMP9 (0.53) | F2MMP9MMP8FCER2MME | |
| SCHEMBL6318655 | 0.81 | GHSR (0.44) | F2MMP9MMP8GHSROPRM1 | |
| SCHEMBL6320694 | 0.79 | MMP9 (0.56) | F2MMP9MMP8FCER2MME | |
| SCHEMBL6317497 | 0.79 | TACR1 (0.41) | F2MMP9MMP8FCER2OPRM1 | |
| SCHEMBL8710938 | 0.78 | MMP9 (0.44) | F2MMP9MMP8FCER2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-6555570-B2 | Growth hormone secretagogous with improved bioavailability | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | F2 2827/4885MMP9 2831/4885MMP8 4280/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | F2 2410/4885MMP9 3090/4885MMP8 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.